MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

88.13 1.44

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

86.42

Máximo

89.56

Métricas clave
By Trading Economics
Ingresos	5.4M -48M
Ventas	6M 57M
Margen de beneficios	-82.974
Empleados	414
EBITDA	5.1M -43M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+76.97% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1.2B 5.3B
Apertura anterior	86.69
Cierre anterior	88.13

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 abr 2026, 22:56 UTC

Noticias de Eventos Importantes

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 abr 2026, 20:50 UTC

Adquisiciones, fusiones, absorciones

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 abr 2026, 23:55 UTC

Charlas de Mercado

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 abr 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 abr 2026, 23:23 UTC

Noticias de Eventos Importantes

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 abr 2026, 23:07 UTC

Ganancias

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 abr 2026, 23:02 UTC

Noticias de Eventos Importantes

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 abr 2026, 23:00 UTC

Noticias de Eventos Importantes

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 abr 2026, 23:00 UTC

Noticias de Eventos Importantes

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 abr 2026, 23:00 UTC

Noticias de Eventos Importantes

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 abr 2026, 22:39 UTC

Ganancias

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 abr 2026, 22:08 UTC

Charlas de Mercado

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 abr 2026, 21:56 UTC

Adquisiciones, fusiones, absorciones

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 abr 2026, 21:31 UTC

Noticias de Eventos Importantes

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 abr 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 abr 2026, 20:38 UTC

Ganancias

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 abr 2026, 20:31 UTC

Adquisiciones, fusiones, absorciones

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 abr 2026, 20:16 UTC

Adquisiciones, fusiones, absorciones

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 abr 2026, 20:16 UTC

Adquisiciones, fusiones, absorciones

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 abr 2026, 20:13 UTC

Adquisiciones, fusiones, absorciones

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 abr 2026, 20:07 UTC

Charlas de Mercado

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 abr 2026, 20:07 UTC

Adquisiciones, fusiones, absorciones

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

76.97% repunte

Estimación a 12 Meses

Media 136.71 USD 76.97%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.